Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development

por Zhu, Wei, Shyr, Zeenat, Lo, Donald C., Zheng, Wei
Publicado 2021

Drug Discovery Strategies for SARS-CoV-2

por Shyr, Zeenat A., Gorshkov, Kirill, Chen, Catherine Z., Zheng, Wei
Publicado 2020

Drug combination therapy for emerging viral diseases

por Shyr, Zeenat A., Cheng, Yu-Shan, Lo, Donald C., Zheng, Wei
Publicado 2021

SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human K(ATP)-induced diabetes through mitigation of oxidative and ER stress

por Shyr, Zeenat A., Yan, Zihan, Ustione, Alessandro, Egan, Erin M., Remedi, Maria S.
Publicado 2022

The role of membrane excitability in pancreatic β-cell glucotoxicity

por Shyr, Zeenat A., Wang, Zhiyu, York, Nathaniel W., Nichols, Colin G., Remedi, Maria S.
Publicado 2019

Genetic Reduction of Glucose Metabolism Preserves Functional β-Cell Mass in K(ATP)-Induced Neonatal Diabetes

por Yan, Zihan, Fortunato, Manuela, Shyr, Zeenat A., Clark, Amy L., Fuess, Matt, Nichols, Colin G., Remedi, Maria S.
Publicado 2022

Beta‐cell excitability and excitability‐driven diabetes in adult Zebrafish islets

por Emfinger, Christopher H., Lőrincz, Réka, Wang, Yixi, York, Nathaniel W., Singareddy, Soma S., Ikle, Jennifer M., Tryon, Robert C., McClenaghan, Conor, Shyr, Zeenat A., Huang, Yan, Reissaus, Christopher A., Meyer, Dirk, Piston, David W., Hyrc, Krzysztof, Remedi, Maria S., Nichols, Colin G.
Publicado 2019